PDUFAoutcome: successconf 0.99

kresladi — PDUFA

$RCKT · ROCKET PHARMACEUTICALS, INC. · Treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant

Event date

March 28, 2026

70 days ago

Sponsor runway

10 mo

$144.4M liquid

Evidence

“The PDUFA date set by the FDA is March 28, 2026.”

Source: 8-K filed 2025-10-14View on EDGAR ↗0001140361-25-038030

Comparable historical pdufas· last 5 years · same indication

0% hit rate (0/1)

Ticker	Drug	Date	Outcome
$RCKT	kresladi	2024-06-30	failure

Recent insider activity· ±90 days

7 insiders · 1 buys · 13 sells

Sell

2026-05-19

Wilson Martin

General Counsel

662 @ $3.01$2K

Sell

2026-05-19

Shah Gaurav

CEO

2,409 @ $3.01$7K

Sell

2026-05-19

Militello John

See Remarks

384 @ $3.01$1K

Sell

2026-05-13

Militello John

See Remarks

855 @ $3.61$3K

Sell

2026-05-13

Wilson Martin

General Counsel

3,361 @ $3.61$12K

Sell

2026-05-13

Shah Gaurav

CEO

2,728 @ $3.61$10K

Sell

2026-05-07

Chaudhuri Sarbani

See Remarks

17,650 @ $3.84$68K

Sell

2026-02-18

Wilson Martin

General Counsel

1,376 @ $3.34$5K

Sell

2026-02-18

Shah Gaurav

CEO

5,990 @ $3.34$20K

Sell

2026-02-18

Militello John

See Remarks

1,157 @ $3.34$4K

Sell

2026-02-13

Wilson Martin

General Counsel

12,253 @ $3.31$41K

Sell

2026-02-13

Militello John

See Remarks

3,726 @ $3.31$12K

Sell

2026-02-13

Shah Gaurav

CEO

12,279 @ $3.31$41K

Grant

2026-02-11

Shah Gaurav

CEO

870,648 @ ——

Grant

2026-02-11

Rizvi Syed Ali-aamir

Chief Medical Officer

93,037 @ ——

Grant

2026-02-11

Chaudhuri Sarbani

See Remarks

125,924 @ ——

Grant

2026-02-11

Chaudhuri Sarbani

See Remarks

189,076 @ ——

Grant

2026-02-11

Stevens Christopher James

Chief Operating Officer

61,963 @ ——

Grant

2026-02-11

Stevens Christopher James

Chief Operating Officer

93,037 @ ——

Grant

2026-02-11

Militello John

See Remarks

29,982 @ ——

Grant

2026-02-11

Militello John

See Remarks

45,018 @ ——

Grant

2026-02-11

Wilson Martin

General Counsel

311,813 @ ——

Grant

2026-02-11

Wilson Martin

General Counsel

468,187 @ ——

Grant

2026-02-11

Rizvi Syed Ali-aamir

Chief Medical Officer

61,963 @ ——

Grant

2026-02-11

Shah Gaurav

CEO

286,028 @ ——

Buy

2026-01-02

Bjork Elisabeth

Director

10,000 @ $3.44$34K

Date	Insider	Action	Shares	Price	Value
2026-05-19	Wilson MartinGeneral Counsel	Sell	662	$3.01	$2K
2026-05-19	Shah GauravCEO	Sell	2,409	$3.01	$7K
2026-05-19	Militello JohnSee Remarks	Sell	384	$3.01	$1K
2026-05-13	Militello JohnSee Remarks	Sell	855	$3.61	$3K
2026-05-13	Wilson MartinGeneral Counsel	Sell	3,361	$3.61	$12K
2026-05-13	Shah GauravCEO	Sell	2,728	$3.61	$10K
2026-05-07	Chaudhuri SarbaniSee Remarks	Sell	17,650	$3.84	$68K
2026-02-18	Wilson MartinGeneral Counsel	Sell	1,376	$3.34	$5K
2026-02-18	Shah GauravCEO	Sell	5,990	$3.34	$20K
2026-02-18	Militello JohnSee Remarks	Sell	1,157	$3.34	$4K
2026-02-13	Wilson MartinGeneral Counsel	Sell	12,253	$3.31	$41K
2026-02-13	Militello JohnSee Remarks	Sell	3,726	$3.31	$12K
2026-02-13	Shah GauravCEO	Sell	12,279	$3.31	$41K
2026-02-11	Shah GauravCEO	Grant	870,648	—	—
2026-02-11	Rizvi Syed Ali-aamirChief Medical Officer	Grant	93,037	—	—
2026-02-11	Chaudhuri SarbaniSee Remarks	Grant	125,924	—	—
2026-02-11	Chaudhuri SarbaniSee Remarks	Grant	189,076	—	—
2026-02-11	Stevens Christopher JamesChief Operating Officer	Grant	61,963	—	—
2026-02-11	Stevens Christopher JamesChief Operating Officer	Grant	93,037	—	—
2026-02-11	Militello JohnSee Remarks	Grant	29,982	—	—
2026-02-11	Militello JohnSee Remarks	Grant	45,018	—	—
2026-02-11	Wilson MartinGeneral Counsel	Grant	311,813	—	—
2026-02-11	Wilson MartinGeneral Counsel	Grant	468,187	—	—
2026-02-11	Rizvi Syed Ali-aamirChief Medical Officer	Grant	61,963	—	—
2026-02-11	Shah GauravCEO	Grant	286,028	—	—
2026-01-02	Bjork ElisabethDirector	Buy	10,000	$3.44	$34K

← All catalysts for $RCKT